Janus Henderson Group PLC Sells 1,161,171 Shares of Envista Holdings Co. (NYSE:NVST)

Janus Henderson Group PLC trimmed its stake in Envista Holdings Co. (NYSE:NVST) by 62.1% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 707,275 shares of the company’s stock after selling 1,161,171 shares during the period. Janus Henderson Group PLC owned approximately 0.41% of Envista worth $15,121,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the stock. Raymond James & Associates raised its holdings in shares of Envista by 820.6% in the fourth quarter. Raymond James & Associates now owns 408,218 shares of the company’s stock worth $9,822,000 after buying an additional 363,875 shares during the period. Pacer Advisors Inc. increased its holdings in Envista by 87.5% during the 4th quarter. Pacer Advisors Inc. now owns 25,770 shares of the company’s stock worth $620,000 after purchasing an additional 12,025 shares during the period. Fifth Third Bancorp increased its holdings in Envista by 98.1% during the 4th quarter. Fifth Third Bancorp now owns 1,254 shares of the company’s stock worth $30,000 after purchasing an additional 621 shares during the period. State of Michigan Retirement System increased its holdings in Envista by 5.1% during the 4th quarter. State of Michigan Retirement System now owns 41,163 shares of the company’s stock worth $990,000 after purchasing an additional 2,000 shares during the period. Finally, DAVENPORT & Co LLC purchased a new position in Envista during the 4th quarter worth $13,233,000.

Envista Stock Performance

Shares of NVST opened at $17.07 on Thursday. The stock has a 50-day moving average of $17.14 and a two-hundred day moving average of $19.83. Envista Holdings Co. has a one year low of $15.69 and a one year high of $36.14. The company has a quick ratio of 1.93, a current ratio of 2.27 and a debt-to-equity ratio of 0.34.

Envista (NYSE:NVST) last issued its quarterly earnings data on Wednesday, May 1st. The company reported $0.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.31 by ($0.05). The company had revenue of $623.60 million during the quarter, compared to analyst estimates of $634.85 million. Envista had a negative net margin of 4.70% and a positive return on equity of 5.84%. The business’s quarterly revenue was down .6% compared to the same quarter last year. During the same period last year, the firm earned $0.38 EPS. On average, research analysts forecast that Envista Holdings Co. will post 1.18 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have commented on NVST. Stifel Nicolaus reduced their price objective on Envista from $20.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday. Needham & Company LLC reiterated a “hold” rating on shares of Envista in a report on Tuesday, July 16th. Evercore ISI cut their price target on Envista from $24.00 to $19.00 and set an “outperform” rating on the stock in a report on Tuesday, June 25th. Robert W. Baird cut their price target on Envista from $19.00 to $17.00 and set a “neutral” rating on the stock in a report on Monday, July 22nd. Finally, Morgan Stanley downgraded Envista from an “overweight” rating to an “equal weight” rating and cut their price target for the company from $33.00 to $21.00 in a report on Friday, April 26th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $19.95.

Envista Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.